跳至主要内容
临床试验/NCT00174330
NCT00174330已完成4 期

A Multi-Center, Randomized, Open-Label Study To Evaluate Efficacy And Safety Of Dual Therapy With Atorvastatin Plus Amlodipine When Compared Amlodipine Therapy Alone In The Treatment Of Subjects With Concurrent Hyperlipidemia And Hypertension.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.15 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2005年5月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
330
试验地点
15
主要终点
To evaluate efficacy of the dual therapy of atorvastatin 10mg or 20mg + amlodipine 5mg or 10mg vs. amlodipine 5mg or 10mg alone

研究概览

简要总结

To evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone .

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects with a diagnosis of both hyperlipidemia and hypertension.

排除标准

  • Subjects with Type 1 diabetes mellitus or Type 2 diabetes mellitus.
  • Subjects with other atherosclerotic disease.

结局指标

主要结局

To evaluate efficacy of the dual therapy of atorvastatin 10mg or 20mg + amlodipine 5mg or 10mg vs. amlodipine 5mg or 10mg alone

次要结局

  • To provide comparative evaluation of the safety profile of the dual therapy with atorvastatin + amlodipine versus amlodipine alone.

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry

研究点 (15)

Loading locations...

相似试验